Member Info for Investinvalue

If we all listened to brokers..experts with no expertise...we would all be broke!

DYOR.

ZAMA spud ready to go and this will be very exciting to be in.

Zama spud is ready to go now. Not in January. The rig is ready.

High chance of success on ZAMA. Rig is in place and crew ready....spud news due!

ZAMA good appraisal will send this up very fast and correction in Oil to boot makes this an ideal time to buy. Big buy order of mine filled

trying to get lower before ZAMA and low oil price. About to reverse.

Aye Aye Captain!

ZAMA

Ensco 8503 rig is in place ready for spud

https://rigspot.net/

Get ready!

lift off!!!

£8 is my conservative price and only then will I topslice for something I have been looking to buy for a while!

the SP is turning...and now heading up. ZAMA Spud....

Imminent.

SPUDDING!

Good post.

Not the new Afren. Afren was lead by thieves. BOD not the issue here, just racking Brent all the way.

Agree. Invested here and staying longterm but PMO follows Brent almost exactly! I will hold off and top up when the SP drops in line with Brent drop.

Huge recovery when oil recovers. Time to think about buying up oil stocks while the SP is on the decline.

Dr Petri Bono, the Principle Investigator of the MATINS trial, said: "I look forward to initiating the MATINS trial patient recruitment since a truly novel approach to break the tumour immune suppression is used in this phaseI/II study. I strongly believe that new immunosuppression releasing approaches (such as anti-Clever-1 antibody) have the potential to become the next wave of cancer treatments"

CTA Process:

http://www.ct-toolkit.ac.uk/routemap/cta-submission/downloads/cta-application-flowchart.pdf

Dr Markku Jalkanen, CEO of Faron, said: "We are making rapid progress with our Clevegen programme and this CTA filing is an important milestone. This precision therapy for cancers with very few treatment options has a unique mechanism of action which, coupled with promising pre-clinical data and human ex-vivo data, already indicates the product's potential in a broad range of indications. We look forward to beginning patient recruitment later this year and moving Clevegen into the clinic."

News is imminent from both Japan and YODA. £8

To understand the reduced biomarker response to Traumakine administration, even where corticosteroids were not administered in the INTEREST study, a new FP-1201-lyo pharmacokinetic/dynamic study, YODA, is already underway in approximately 50 healthy volunteers. This will determine the optimum mechanism of administration to achieve a full biomarker response with first results expected in Q4 2018. The YODA study may also be extended to examine concomitant use of Traumakine and corticosteroids to get final in vivo evidence for corticosteroid interference of interaction activity.

Oversold

I THOUGHT THESE WERE FULLY FUNDED?